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Abstract
Objective—The purpose of this study was to assess the cross-sectional association between 
serum/urine biomarkers for osteoarthritis and MR-based cartilage composition and joint 
morphology of the knee, assessed using MR imaging data from the Osteoarthritis Initiative (OAI).
Design—141 subjects with Kellgren Lawrence (KL) grades 0–3 in the right knee and with 
available serum/urine biomarker assays were selected from the OAI. Cartilage T2 measurements 
were performed in the medial femur, lateral femur, medial tibia, lateral tibia, and patella 
compartments. Compartment-specific knee morphologic grading (WORMS) in the cartilage, 
meniscus, and bone marrow was also performed. We focused on associations of serum hyaluronan 
(sHA), serum COMP (sCOMP), serum MMP3 (sMMP3), and Urine CTX-II (uCtX-II)) with MRI 
parameters (T2, WORMS), assessed using partial correlations adjusted for age, gender, BMI, KL 
grade in both knees, and diabetes status.
Results—Higher levels of sHA, sMMP3 and sCOMP were correlated (p<0.05) with T2 of the 
lateral femur (r=0.18 to 0.32) and lateral tibia (r=0.17 to 0.23), and with average T2 of all knee 
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regions (r=0.23). uCTXII was correlated with patellar T2 (r=0.19, P=0.04). Among the 
morphologic measures, sHA and sMMP3 was positively correlated (r=0.17 to 0.19, p<0.05) with 
meniscal damage.
Conclusions—This study suggests weak, but statistically significant, correlations of sHA, and 
sMMP3 with MRI T2 measures of cartilage extra-cellular matrix degeneration.
INTRODUCTION
Osteoarthritis (OA) is a heterogeneous joint disease that affects approximately 250 million 
people [1], causes severe disability [2], and often leads to total knee replacement (TKR). 
The rising rates of TKR [3] highlight a need to develop biomarkers that can detect early 
stages of joint degeneration. Ideally, such biomarkers would identify high-risk subjects that 
would most benefit from therapeutic intervention, such as lifestyle modification.
Biochemical serum and urine markers of OA are molecules that are released into serum/
urine reflecting cartilage or bone turnover and the repair and regeneration processes that 
occur in joint tissue [4]. These markers are associated with radiographic OA changes, 
particularly the late stages of disease; Vilim et al. reported that serum COMP is associated 
with radiographic progression of OA [5], urine CTX-II is associated with progression in 
joint space narrowing (JSN) [6] and serum hyaluronan is associated with incidence of knee 
JSN [7]. However, few have studied the relationships of OA serum/urine markers with MR 
imaging markers of knee cartilage composition and morphologic knee damage which are not 
appreciated on standard radiographs [8].
Degenerative cartilage compositional change in OA can be quantified using MRI T2 
mapping, that identifies abnormalities of the cartilage extracellular matrix including collagen 
fiber orientation[9]. MRI T2 probes early stages of cartilage degeneration, which are not 
seen on standard MRI, occurring prior to macroscopic cartilage defects and thinning. 
Understanding the links between systemic markers of knee joint tissue degeneration/repair 
expressed in serum/urine and imaging measures of changes in cartilage composition would 
provide new insights into the role of systemic biomarkers in assessing joint degeneration at 
early disease stages. Thus, serum/urine biomarkers could potentially provide information on 
the risk for developing OA at a pre-clinical stage.
The purpose of this study was therefore to assess the relationships of serum/urine 
biomarkers for osteoarthritis with MR imaging measures of joint structure (cartilage, 
meniscus, and bone marrow) and cartilage composition, using data from the Osteoarthritis 
Initiative (OAI).
METHODS
Subject Selection
This study utilizes data from the Osteoarthritis Initiative (OAI; http://www.oai.ucsf.edu/)
[10], a multi-center, longitudinal study of persons aged 45–79 years at enrollment, aimed at 
assessing biomarkers in OA including those derived from MR imaging. The OAI dataset 
includes both MRI and radiographic images of subjects scanned over eight years. This 
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database can be used to evaluate MRI biomarkers for the development and progression of 
OA. The study protocol, amendments, and informed consent documentation were reviewed 
and approved by the local institutional review boards of all participating centers.
Subjects in this study are a subset of those included in the FNIH OARSI Biomarkers 
Consortium study, a nested case-control study within the OAI of 600 knees (one knee per 
subject) with structural and/or symptom progression over 4 years and knees that did not 
progress. Details of the study design are available [11]. Subjects in that study had serum and 
urine OA biomarkers assessed at baseline, 12 and 24 months. For the present study, we 
analyzed a convenience sample of these subjects by selecting all subjects that had a Kellgren 
Lawrence score (KL) ≤ 3 in a right knee from which we had previously obtained both T2 
and joint morphology measures from the OAI MR images for other analyses.[12–16]. The 
OAI exclusion criteria was: (i) inflammatory arthropathies (including rheumatoid arthritis 
and seronegative spondylarthropathies), (ii) MRI contraindications, (iii) use of ambulatory 
aids and co-morbid conditions that may affect the ability to participate in the study. For this 
analysis we further excluded knees with (i) knee injury with deformity of the knee joint, (ii) 
total joint replacements at the lower extremities, (iii) MRI evidence of fractures or 
abnormalities, that do not fit into the spectrum of OA and may indicate other severe disease, 
such as tumor or inflammation.
Serum and Urine Biomarkers
Morning blood and second morning void urine specimens were collected after an overnight 
fast using a uniform protocol at baseline, 12 month and 24 month clinic visits. Additional 
details on specimen collection and processing methods can be found in the OAI operations 
manuals (http://www.oai.ucsf.edu/datarelease/OperationsManuals.asp). Among the eighteen 
serum and urine biomarkers available from the Biomarkers Consortium study, we focused on 
four based on previous research studies and recommendations from a consensus document 
from the Osteoarthritis Research Society International (OARSI) US FDA initiative [17]. 
These were: serum cartilage oligomeric matrix protein (sCOMP), serum hyaluronan (sHA), 
serum matrix metalloproteinase-3 (sMMP3), and urine Carboxy-Terminal Telepeptides of 
Type II Collagen (uCTXII) [7, 17–21]. We performed exploratory analyses of the remaining 
biomarkers: serum PIIANP (sPIIANP), serum CTXI (sCTXI), Serum CS846 (sCS846), 
Serum C2C (sC2C), Serum C1,2C (sC12c), Serum CPII (sCPII), Serum NTXI (sNTXI), 
Serum Coll2 1 NO2 (sColl21NO2), urine NTXI (uNTXI), urine C1,2C (uC12C), and urine 
Coll2 1 NO2 (uColl21NO2) [17]. The primary and exploratory predictors are summarized in 
Table 1.
All biomarker assays were performed by LabCorp ClinicalTrials, a Clinical Laboratory 
Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified 
division within LabCorp, with the exception of urine Col2-1 NO2, which was measured by 
clinical information. Complete details have been published [22, 23].
MR Imaging
MR images were obtained using four identical 3.0 Tesla (Siemens Magnetom Trio, 
Erlangen, Germany) scanners in Columbus, Ohio; Baltimore, Maryland; Pittsburgh, 
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Pennsylvania; Pawtucket, Rhode Island. The following sequences were acquired: sagittal 2D 
intermediate-weighted fast spin-echo sequence (repetition time (TR)/echo time 
(TE)=3200/30ms, spatial resolution=0.357mm×0.511mm, slice thickness=3.0mm), coronal 
2D proton density fast spin-echo sequence (TR/TE=3700/29ms, spatial 
resolution=0.365mm×0.456mm, slice thickness=3.0mm), and sagittal 3D dual-echo in 
steady state sequence (TR/TE=16.3/4.7ms, spatial resolution=0.365mmx0.456mm, slice 
thickness=0.7mm). A sagittal 2D multi-slice multi-echo sequence (MSME, TR=2700ms, 
TE1-TE7=10-70ms, spatial resolution=0.313mm×0.446mm, slice thickness=3.0mm, and 
0.5mm gap) was used for cartilage T2 measurements[24].
Image Analysis
X-ray based KL grade and Joint space Narrowing—Fixed Flexion knee radiographs 
were obtained at baseline, and radiographic KL grades[25] were provided in the OAI 
dataset. Subjects with baseline KL grades of 0–3 were selected. Joint space narrowing (JSN) 
scores at baseline and two years were provided in the OAI dataset. JSN progression (in the 
right or left knee, individually) was defined as positive if a knee had a ≥ 1 OARSI grade 
increase in JSN score (medial or lateral) between baseline and two years.
WORMS Scoring—MR images of the right knee obtained at the baseline visit were 
reviewed on picture archiving communication system (PACS) workstations (Agfa, 
Ridgefield Park, NJ, USA). Three radiologists with 7-, 5- and 5-years of experience graded 
cartilage lesions. In equivocal cases, a consensus reading was performed with a 
musculoskeletal radiologist with 24-years of experience. Baseline cartilage and bone marrow 
lesions were assessed in six regions (patella, trochlea, medial femur, medial tibia, lateral 
femur and lateral tibia) using a modified semi-quantitative whole-organ magnetic resonance 
imaging score (WORMS) [26]. The highest score of any lesion was recorded for each 
region.
Subchondral bone marrow edema pattern was defined as poorly marginated areas of 
increased T2 signal intensity and graded using a modified 4-point WORMS scale (0, none; 
1, diameter 0–5mm; 2, 5–20mm; 3, >20mm) [27]. Meniscal lesions were graded separately 
in 6 regions (medial/lateral and anterior/body/posterior) using the following 4-point scale: 0-
normal; 1-intrasubstance signal; 2-non-displaced tear; 3-displaced or complex tear; 4-
complete destruction/maceration.
The maximum (MAX) cartilage, meniscus or bone marrow edema (BME) score was defined 
as the maximum score in any region. The summation (SUM) cartilage, meniscus or BME 
score was defined as the summation of WORMS scores in all regions. The reproducibility 
results for WORMS reading have been previously published [28, 29]: the intra-observer 
reproducibility in all tissues (meniscus, cartilage, bone marrow) was ≥96%, while the inter-
observer reproducibility was ≥97%.
T2 measurements—Semi-automatic cartilage segmentation of lateral/medial femur, 
lateral/medial tibia, and patella regions was performed as previously described, using an in-
house, spline-based software based on MATLAB (MathWorks, Natick, Massachusetts)[29]. 
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Trained investigators segmented the entire cartilage but used rigorous criteria to exclude 
sections with compromised image quality.
Validated methods for obtaining a T2 map of the cartilage have been published [28, 29]. T2 
maps were computed from the MSME images on a pixel-by-pixel basis using 6 echoes 
(TE=20–70ms) and 3 parameter fittings accounting for noise [30, 31], and averaged over all 
of the slices in each cartilage region. The first echo (TE=10ms) was not included in the T2 
fitting procedure in order to reduce potential errors resulting from stimulated echoes, and a 
noise-corrected algorithm was implemented [30, 31]. The cartilage T2 reproducibility results 
have been described previously [28, 29]. The mean T2 values had root mean square (RMS) 
coefficients of variation (CV) ranging from 0.83% in the medial femur to 3.21% in the 
patella for intra-reader reproducibility, and from 1.22% in the patella to 1.86% in the lateral 
tibia for inter-reader reproducibility.
Statistical Analysis
Statistical analysis was performed using STATA version 14 software (StataCorp LP, College 
Station, TX). Due to large between-subject variations [32], the dynamic nature of the serum 
markers due to nonlinear or phasic progression [22], and large variations of serum markers 
over time [32], we averaged the values of the serum and urine biomarkers, respectively, over 
the three measured timepoints (baseline, 12 and 24 months). For the cross-sectional analysis, 
partial correlations adjusted for age, gender, BMI, KL grade in both knees, diabetes status 
were used to evaluate the associations between serum/urine biomarkers and the following 
outcome variables: cartilage T2, cartilage, meniscus, and bone marrow lesion WORMS 
scores. The associations between biomarkers and both KL grade and WOMAC pain scores 
were assessed using partial correlations adjusted for adjusted for age, gender, and BMI. All 
the assumptions for partial correlation analysis were fulfilled.
We also performed longitudinal analyses of biochemical measures from baseline, 12 months 
and 24 months, using linear mixed effects models accounting for multiple measurements per 
subject. We assessed whether annual rates of change in biomarkers differed by baseline 
measures of (1) presence of a partial thickness cartilage defects (WORMS 0/1 vs. WORMS 
≥2) and (2) presence of a meniscus tear (WORMS 0/1 vs. WORMS ≥2), and (3) average T2 
subdivided by tertiles, by including an interaction between timepoint and each respective 
subgroup. The analyses of cartilage defects and T2 tertiles were adjusted for age, gender, 
BMI, KL grade in both knees, and diabetes status.
RESULTS
Subject Characteristics
The 141 participants in this study had a mean age of 59.7±8.3 years and a mean BMI of 
29.9±4.5 kg/m2 at baseline. Sixty-six percent of the subjects were female, and a majority of 
the subjects had KL2 (n = 66, 46.8%), while 9.2% (n=13) had KL0, 14.9% (n=21) had KL1, 
and 29.1% (n=41) had KL3. Twelve subjects (8.5%) had JSN in the left knee over two years, 
while fifteen subjects (10.6%) had JSN in the right knee over two years (Table 2).
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No significant associations were found between the primary biomarkers (sHA, sCOMP, 
sMMP3, uCTXII) and KL grade or WOMAC pain score (adjusted for age, gender, and BMI, 
Supplementary Table 1) at baseline. No significant associations were found between blood 
biomarkers and development of joint space narrowing in the right knee over 2 years (n=15, 
10.6% of subjects): uCTXII (OR = 1.17; p=0.61, 95% CI: 0.74–1.65), sMMP3 (OR=1.03, 
p=0.26, 95% CI: 0.97–1.11), sCOMP (OR = 1.01, p=0.71, 95% CI: 0.99–1.02), and sHA 
(OR =1.01 p=0.11, 95% CI: 0.99–1.04).
Cartilage MRI T2
Serum biomarkers sHA, sCOMP, and sMMP3 were positively correlated with cartilage T2 
values (Table 3). For sHA, significant associations were found with T2 averaged over all 
cartilage compartments (r=0.23, p=0.01, 95% CI: 0.06–0.41), lateral femur T2 (r=0.32, 
p=0.001, 95% CI: 0.16–0.50) and lateral tibia T2 (r=0.20, p=0.01, 95% CI: 0.03–0.37), 
Table 3 and Figure 1. sCOMP showed positive associations with cartilage T2 in the lateral 
femur (r=0.18, p=0.03, 95% CI: 0.01–0.35) and the lateral tibia (r=0.17, p=0.04, 95% CI: 
0.00–0.34). sMMP3 showed positive associations with cartilage T2 in the average of all 
compartments (r=0.23, p=0.006, 95% CI: 0.06–0.41), the lateral femur (r=0.18, p=0.03, 95% 
CI: 0.01–0.35), and the lateral tibia (r=0.23, p=0.01, 95% CI: 0.06–0.41), Figure 2. uCTXII 
was positively associated with cartilage T2 in the patella (r=0.19, p=0.04, 95% CI: 0.02–
0.36). Many significant associations were found between the exploratory predictors and 
serum/urine biomarkers, especially Coll21NO2 (Supplementary Table 3).
Interestingly, when subdividing the partial correlations between subjects with KL 0/1 and 
subjects with KL 2/3: subjects with KL 0 or 1 (n=34) had higher correlations between 
sMMP3 and cartilage parameters compared to subjects with KL 2 or 3, and compared to the 
entire cohort. The correlations between sMMP3 and cartilage parameters in subjects with 
KL 0 or 1 were significant in the average of all compartments: (r=0.52, p=0.004, 95% CI: 
0.41–0.75), patella (r=0.41, p=0.03, 95% CI: 0.26–0.61), and medial tibia (r=0.48, p=0.009, 
95% CI: 0.35–0.69). In subjects with KL 2 or 3 (n=107), the correlations between sMMP3 
and T2 parameters were not significant: average of all compartments: (r=0.14, p=0.14, 95% 
CI: −0.03–0.31), patella (r=0.02, p=0.80, 95% CI: −0.15–0.19), and medial tibia (r=0.09, 
p=0.37, 95% CI: −0.08–0.26). However, subjects with KL 2 or 3 had significant correlations 
between sHA and T2 parameters (average of all compartments r=0.25, p=0.009, 95% CI: 
0.08–0.43; lateral femur r=0.30, p=0.002, 95% CI: 0.14–0.48 and the lateral tibia r=0.23, 
p=0.02, 95% CI: −0.06–0.41). The correlations between T2 and sCOMP were not 
significantly different when subdivided by KL grade.
Joint Morphology
There were no significant associations between the primary serum/urine biomarkers and 
cartilage WORMS scores, Table 3. sHA was significantly correlated with meniscus 
WORMS scores for the medial body (r=0.19, p=0.02, 95% CI: 0.02–0.36), and maximum 
score of all regions (r=0.17, p=0.05, 95% CI: 0.00–0.34), Table 3. sMMP3 was significantly 
correlated with meniscus WORMS scores for the medial body (r=0.21, p=0.01, 95% CI: 
0.04–0.38), lateral anterior horn (r=0.18, p=0.04, 95% CI: 0.01–0.35), lateral body (r=0.19, 
p=0.02, 95% CI: 0.02–0.36) and maximum score of all regions (r=0.19, p=0.02, 95% CI: 
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0.02–0.36), Table 3. sCOMP and uCTXII were not significantly associated with meniscus 
WORMS scores. The only significant association between serum/urine biomarkers and bone 
marrow abnormalities graded by the WORMS score was with sMMP3 for the lateral tibia 
(r=0.20, p=0.02, 95% CI: 0.03–0.37), Supplementary Table 2. For the exploratory predictors, 
significant associations were found between joint morphology and biomarkers including 
Coll21NO2, Supplementary Table 3. We also performed a sensitivity analysis in only 
subjects with medial JSN at baseline (61%) and found similar results to those of the entire 
sample. There were only 3 subjects with lateral JSN in the sample, thus a sensitivity analysis 
in these subjects could not be performed.
Longitudinal Changes in Biomarkers
Subjects had significant increases in sHA over 2 years (increase (ng/mL)/year =4.3, 
p<0.0001, 95% CI: 2.15–6.36). The longitudinal changes in sCOMP (-1.06 ng/mL/year; 
p=0.87, 95% CI: −13.9–11.8), sMMP3 (−0.07 ng/mL/year; p=0.80, 95% CI: − 0.62–0.49), 
and uCTXII (1.58 ng/mmol Cr/year; p=0.10, 95% CI: −0.03–0.35) were not significant. 
Both baseline T2 and presence of a cartilage defect were not significantly associated with 
the rate of change in sHA over 2 years (p=0.77 respectively p=0.99); however, subjects with 
meniscus tears showed increases in sHA over time (coeff=3.86, p=0.08, 95% CI: −0.53–
8.26) compared to subjects without meniscus tears.
While subjects with cartilage defects at baseline had consistently higher sHA values than 
subjects without defects over 2 years, the differences were not significant (coeff=8.37, 
p=0.13, 95% CI: −2.54–19.28). However, subjects with high T2 values (averaged over all 
compartments) at baseline had significantly greater sHA than subjects with low T2 values 
(T2 Tertile 3 vs. T2 Tertile 1: coeff=14.82, p=0.01, 95% CI: 3.41–26.19) suggesting that 
subjects with cartilage biochemical abnormalities at baseline had consistently increased 
expression of sHA over 2 years, Figure 3. Similarly, subjects with high T2 values (averaged 
over all compartments) at baseline had significantly greater sMMP3 (T2 Tertile 3 vs. T2 
Tertile 1: coeff=4.74, p=0.006, 95% CI: 1.34–8.13), sCOMP (T2 Tertile 3 vs. T2 Tertile 1: 
coeff=131.51, p=0.01, 95% CI: 26.59–236.43), and uCTXII (T2 Tertile 3 vs. T2 Tertile 1: 
coeff= 0.72, p=0.04, 95% CI: 0.02–1.43) than subjects with low T2 values.
DISCUSSION
Our study has shown significant positive correlations between the serum biomarkers (sHA, 
sMMP3, sCOMP), and cartilage T2, a measure of early cartilage degeneration. However, no 
significant associations were found between the primary serum/urine biomarkers and 
cartilage morphology or KL grade. While the correlations between serum/urine biomarkers 
and cartilage T2 were relatively low but significant (r~0.20), the results suggest that serum 
biomarkers may be sensitive to biochemical changes in cartilage that may not be related to 
morphologic damage and may thus represent early cartilage matrix degeneration.
One of the strengths of the current study is its focus on quantifying early biochemical stages 
of cartilage degeneration using cartilage T2 mapping. While previous research studies on 
serum/urine markers in OA have primarily focused on radiographic OA [5–7], few studies 
have investigated the relationships between biomarkers and cartilage compositional markers. 
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One study targeting early arthroscopic finding in OA [33] reported positive associations 
between sHA, sCOMP and arthroscopic findings of cartilage softening and swelling 
(Outerbridge score of 1) and partial thickness defects (Outerbridge score of 2). Our study 
found similar results showing positive correlations between sHA, sCOMP and early 
cartilage biochemical degeneration associated with elevated cartilage T2. Interestingly, a 
high baseline T2 (>66th percentile) was also associated with consistently higher levels of 
sHA over 2 years of follow-up. One mechanism that may explain the relationship between 
cartilage degeneration and HA was suggested by Jiao et al.: that cartilage damage may 
initiate a pathologic inflammatory response, which promotes increases in HA production by 
the inflamed synovium [33]. Overall, our study demonstrates positive associations between 
serum marker sHA, suggesting that these markers are associated with early biochemical 
changes in the cartilage ECM matrix.
Studies have reported varying results on the associations between serum/urine biomarkers 
and knee morphology. Hunter et al. reported positive correlations with cartilage loss (for a 1-
unit increase in COMP, the odds of cartilage loss increased 6.09 times (95% confidence 
interval [CI] 1.34 to 27.67)[34], while Eckstein et al, found that uCTXII and sCOMP were 
not associated longitudinal cartilage thinning over 24 months [35]. Another study reported 
no associations between baseline biochemical markers and cartilage volume or thickness, 
but changes in CTXII over three months were associated with decreases in cartilage 
thickness over one year[4]. Our study found no significant correlations between the primary 
serum/urine biomarkers and cartilage WORMS scores, suggesting that focal cartilage 
damage is not associated with sCOMP, sHA, sMMP3, and uCTXII, and may potentially be 
related to focal rather than diffuse abnormality of the cartilage.
Interestingly one of the exploratory, less-well established predictors, Coll21NO2, was 
associated with cartilage T2, cartilage WORMS, and meniscus WORMS scores n various 
compartments (Supplementary Table 3). This biomarker is related to collagen Type II 
degradation and may reflect oxidative-related cartilage degeneration [36]. Studies have 
shown elevated Coll21NO2 in subjects with OA [36], and increases in these peptides over 1 
year were predictive of radiographic knee OA progression[37]. Thus, Coll21NO2 may be an 
important biomarker that to be considered for future longitudinal evaluation.
In this study, no significant associations between KL score and biochemical markers were 
found. Previous studies have reported varied results: Golightly et al. [7] showed positive 
higher baseline COMP and HA levels were associated with incident knee OA over an 
average follow-up period of 6.3 years, while Bruyere et al. reported no cross-sectional 
associations between biochemical markers (serum keratan sulphate, serum hyaluronic acid, 
urine pyridinoline and deoxypyridinoline, serumosteocalcin, and COMP) and femoro-tibial 
joint space width in more than 200 patients with knee OA [38]. In this study, perhaps, the 
non-significant associations between biochemical markers and KL score may be attributed to 
its cross-sectional nature and uneven distribution of KL grade, weighted toward knee KL 2: 
almost half of the subjects (46.8%, n=66) had a KL 2.
Ideally, biomarkers could be used as diagnostic tools to identify subjects at high risk for the 
development or progression of OA at which point therapy is most effective, or to test 
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efficacy of therapeutic intervention. Serum/urine biomarkers are dynamic in nature [22, 32], 
could represent a delayed biological event that may have occurred in the joint, and are 
affected by injury [39] or exercise [40]. In contrast, MRI and X-ray imaging offer a more 
stable evaluation of joint structures, and vary more slowly over time. Accordingly, the 
relatively low correlations in this study (r~0.2) were not unexpected, highlighting the 
heterogeneity of OA, and that the systemic biomarker changes may only partially explain the 
biochemical composition captured with MRI T2 during degeneration. Clinically, we believe 
that both serum biomarkers and MR imaging data provide complementary information 
comprising both the dynamic changes occurring during joint degeneration and overall 
disease status, thus highlighting the need for longitudinal evaluations of long-term 
prognostic value.
There are several limitations of this study: we only analyzed T2 measurements of cartilage 
composition as provided by the OAI, and it would be beneficial to study other quantitative 
cartilage assessments such as T1rho mapping. In addition, no significant associations were 
found between serum/urine biomarkers and knee pain score. These results may be due to the 
fact that subjects in this study had low knee pain (mean WOMAC knee pain score = 2.6 
± 3.3) based on the WOMAC knee pain scale, which ranges from 0–20. The statistically 
significant association between uCTXII with patellar disease is unexpected, and this 
relationship may be due to multiple testing (as we did not adjust for multiple outcomes). A 
large number of analyses were performed in this study and thus the results should be 
interpreted with caution. Despite these limitations, we feel that this study is unique: it is the 
first to assess the relationships between serum/urine biomarkers and MRI cartilage 
biochemical composition quantified using cartilage T2.
Overall, this study suggests weak but significant associations between serum biochemical 
markers of OA (sHA, sMMP3, sCOMP) and MRI T2 biochemical degeneration of the 
cartilage ECM. Based on our results, serum biomarkers and cartilage T2 composition may 
reflect similar features of the pathophysiology of cartilage matrix degenerative disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Scatterplots with a line fit using linear regression illustrate the associations between sHA 
and Cartilage T2. Partial correlations are listed with adjustments for age, gender, BMI, 
diabetes status, KL grade in both knees, and JSN over 2 years in both knees).
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Figure 2. 
Randomly selected cartilage T2 maps in subject with low sMMP3 of 8.3 ~ 20th percentile (a) 
and a subject with high sMMP3 29.9 ~ 90th percentile (b). The subject with high sMMP3 
values also has high T2 values (in ms), as shown by the red areas in the cartilage.
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Figure 3. 
Mixed random effects models of absolute rates of change in sHA (with 95% confidence 
intervals) subdivided by (a) presence of a partial thickness cartilage defect in a knee, (b) 
presence of a meniscal tear and (c) T2 values (averaged over all compartments) subdivided 
into tertiles. Timepoint “0” indicates baseline.
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Table 1
Serum and urine biomarkers analyzed in this study.
Biomarkers Manufacturer Biological Process [22]
Primary Predictors
Serum COMP (sCOMP) Biovendor Cartilage degradation
Serum hyaluronan (sHA) Corgenix Osteophyte burden, synovitis
Serum MMP-3 (sMMP3) Invitrogen Total (active and inactive) metalloprotease involved with joint 
tissue degradation
Urine CTXII (uCTXII) Biovendor Type II collagen degradation
Exploratory Predictors
Serum PIIANP (sPIIANP) Merck Group/Millipore Type II collagen synthesis
Serum CTXI (sCTXI) IDS Bone resorption
Serum CS846 (sCS846) IBEX Cartilage aggrecan synthesis/turnover
Serum C2C (sC2C) IBEX Type II collagen degradation
Serum CPII (sCPIl) IBEX Type II collagen synthesis
Serum/Urine NTXI (sNTXI/uNTXI) ALERE - Osteomark Bone resorption
Serum/Urine Coll2 1 NO2 (sColl21 NO2/
uColl21 NO2)
Artialis Type II collagen degradation and inflammation
Serum/Urine C1,2C (sC12C/uC12C) IBEX Types 1 and II collagen degradation
Abbreviations: COMP, cartilage oligomeric matrix protein; CTXII, C-terminal crosslinked telopeptide type II collagen; PIIANP, type IIA 
procollagen amino terminal propeptide; CTXI, C-terminal crosslinked telopeptide of type I collagen; CS846, chondroitin sulfate 846 epitope; C2C, 
Collagen Type II Cleavage; CPII, C-propeptide of type II collagen; NTXI, N-telopeptide of type I collagen. All biomarker assays were performed 
by LabCorp Clinical Trials, a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified 
division within LabCorp, with the exception of urine Col2-1 NO2, which was measured by Artialis, a Good Laboratory Practice-certified facility.
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Table 2
Participant Characteristics.
All Participants
n 141
Age (years) 59.7 ± 8.2
BMI (kg/m2) 29.9 ± 4.5
Gender (female) 93 (65.9%)
WOMAC* pain 2.6 ± 3.3
Family history of knee replacement 27 (19.4%)
Subjects with type 2 diabetes 12 (8.7%)
Right knee KL
 0 13 (9.2%)
 1 21 (14.9%)
 2 66 (46.8%)
 3 41 (29.1%)
Left knee KL
 0 20 (14.2%)
 1 25 (17.7%)
 2 55 (39.0%)
 3 37 (26.2%)
 4 4 (2.8%)
Right knee JSN over two years 15 (10.6%)
Left knee JSN over two years 12 (8.5%)
*WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index
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